Creating New Possibilities for Children Living with CLN6 Disease
The Charlotte and Gwenyth Gray Foundation is dedicated to accelerating the development of therapies for children affected by CLN6 Batten disease, an ultra-rare and fatal pediatric neurodegenerative disorder with no curative treatment options. As a family-led organization, the foundation works to bridge the gap between scientific discovery and clinical translation, helping advance promising therapies for patient populations that are often overlooked by traditional drug development models.
For families facing a CLN6 diagnosis, time is the most precious resource. The ultimate goal is to slow disease progression, preserve neurological function, and create the possibility of more meaningful milestones, memories, and quality of life for affected children.
The Challenge
The foundation faced the complex challenge of relaunching a legacy Investigational New Drug (IND) program under a new manufacturing process while simultaneously advancing an urgently needed gene therapy for CLN6 Batten disease. This required navigating significant manufacturing, comparability, regulatory, and operational considerations while maintaining momentum toward clinical readiness.
For a rapidly progressive pediatric neurodegenerative disease, delays can have profound consequences. The program required a manufacturing partner capable of balancing scientific rigor and regulatory expectations with the flexibility and urgency needed to support children who simply do not have time to wait.
As a family-led nonprofit organization, the foundation does not maintain internal GMP manufacturing capabilities and relies on external partners with highly specialized expertise. Traditional manufacturing models are often not designed to support ultra-rare disease programs that require close collaboration, individualized attention, and the ability to adapt quickly to evolving needs.
The Solution
Genezen brought together deep expertise in viral vector manufacturing, technical execution, and quality-focused program management to help support the program through critical manufacturing activities required for clinical advancement. More importantly, they approached the collaboration as a true partner, providing scientific guidance, operational support, and strategic input throughout the process.
Recognizing the unique demands of a family-led rare disease initiative, Genezen maintained a highly engaged and responsive approach, enabling close communication and rapid problem-solving as regulatory requirements and program priorities evolved. Their team contributed to discussions around manufacturing planning, risk management, technical troubleshooting, and timeline optimization, helping the foundation navigate complex challenges while maintaining forward momentum.
Beyond technical capabilities, Genezen demonstrated a clear understanding of the mission driving the program. Their compassion, transparency, and commitment to collaboration helped support an organization carrying both the operational responsibility and emotional weight of advancing a potentially life-changing therapy for children with CLN6 disease.
Importantly, Genezen also showed exceptional flexibility in navigating the unique operational and financial realities often faced by family-led ultra-rare disease programs. Their willingness to work collaboratively and creatively through complex challenges helped ensure critical progress could continue at key moments when delays may have significantly impacted the path toward clinical development.
“The partners who matter most are the ones who recognize the humanity behind the program and embrace the urgency alongside us. Throughout this collaboration, Genezen consistently demonstrated not only technical excellence, but also compassion, flexibility, and a genuine commitment to helping families like ours fight for a future that once felt impossible.”
— Anonymous —
